Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vysis's Ship Comes In

Executive Summary

Not too long ago, Vysis was just one of dozens of struggling genomic start-ups. Now, however, with its pending acquisition by Abbott Laboratories, it is a poster child for genomics success. Abbott is betting on the potential of Vysis's core position in fluorescent in situ hybridization (FISH) as a diagnostic tool, which allows users to evaluate disease based on changes at the chromosomal level. Abbott has been marketing Vysis's FISH test for the HER2 gene and since this summer.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel